SCHEMBL6304204

SCHEMBL6304204

Cc1cccc(NC(=S)NC2CCCC2N2CCC(Cc3ccc(Cl)cc3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ NLRP3 Q96P20 1/20 0.43
▸ F10 P00742 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CXCR4 P61073 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6304207 1.00 FAAH (0.48) FAAHSMN1; SMN2HPGDALOX12NLRP3
SCHEMBL6303668 0.92 KMT2A (0.49) MEN1KMT2AMAPTHTTCYP2D6
SCHEMBL6303744 0.89 FAAH (0.52) FAAHSMN1; SMN2NLRP3DRD2DRD4
SCHEMBL6303748 0.89 FAAH (0.52) FAAHSMN1; SMN2NLRP3DRD2DRD4
SCHEMBL6303831 0.89 POLB (0.44) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL6303829 0.89 POLB (0.44) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL6310706 0.83 ALDH1A1 (0.48) SMN1; SMN2HPGDALOX12MEN1KMT2A
SCHEMBL6310709 0.83 ALDH1A1 (0.48) SMN1; SMN2HPGDALOX12MEN1KMT2A
SCHEMBL6303726 0.83 SMN1; SMN2 (0.46) SMN1; SMN2HPGDALOX12MEN1KMT2A
SCHEMBL6303723 0.83 SMN1; SMN2 (0.46) SMN1; SMN2HPGDALOX12MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977265-B2 Piperidine CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2005-12-20 — — US disclosed
US-20030229121-A1 Piperidine CCR-3 receptor antagonists SYNTEX (U.S.A.) LLC 2003-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229121-A1 Piperidine CCR-3 receptor antagonists CCR1, CCR3, CCRL2 FAAH 1329/4885SMN1; SMN2 3011/4885HPGD 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback